跳至主要内容
临床试验/NCT00929565
NCT00929565已完成不适用

Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.

University of Oklahoma1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2009年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1

研究概览

简要总结

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.

详细描述

This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any patient scheduled to undergo bronchoscopy

排除标准

  • Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
  • Patients not scheduled to undergo bronchoalveolar lavage (BAL)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gary Kinasewitz

Principal Investigator

University of Oklahoma

研究点 (1)

Loading locations...

相似试验